PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
β-elemene is approved in China for treating advanced and metastatic hepatocellular carcinoma (HCC) and various cancers [PMID:40347926, 33801899].
Ethyl acetate fraction of extract alleviated cognitive deficits and restrained pyroptosis in Aβ1-42-induced mice [PMID:39954619].
Petroleum ether fraction reduced body weight, serum total cholesterol, and liver triglycerides in high-fat diet LDLR knockout mice [PMID:38604260].
Elema-1,3,7(11),8-tetraen-8,12-lactam showed therapeutic potential via anti-inflammatory and anti-angiogenic pathways [PMID:37414197].
Root aqueous extracts demonstrated endothelial protective effects against LPS-induced damage in rats [PMID:40959576].
Evidence summary
PubMed sources
- 1.PMID: 39954619 (2025) — Curcuma wenyujin extract alleviates cognitive deficits and restrains pyroptosis through PINK1/Parkin mediated autophagy in Alzheimer's disease. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 2.PMID: 37689240 (2024) — β-Elemene induced ferroptosis via TFEB-mediated GPX4 degradation in EGFR wide-type non-small cell lung cancer. · Journal of advanced research
- 3.PMID: 35306002 (2022) — Guaiane-type sesquiterpenes from Curcumawenyujin. · Phytochemistry
- 4.PMID: 36336136 (2022) — Four new sesquiterpenes from Curcuma wenyujin. · Fitoterapia
- 5.PMID: 38604260 (2024) — Curcuma wenyujin rhizomes extract ameliorates lipid accumulation.